Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Kisspeptin-10 and Melanotan II — mechanism, side effects, legal status, and pricing.
Kisspeptin-10 (KP-10) is the 10-amino-acid C-terminal fragment of kisspeptin (the KISS1 gene product, also called metastin) that retains full biological activity. It is an investigational signaling peptide that sits at the top of the reproductive axis and is studied for fertility, hypogonadism, and as a diagnostic challenge. It is not FDA-approved.
Melanotan II (MT-II) is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) — Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 — developed at the University of Arizona in the 1980s by Hruby, Hadley, and colleagues as a candidate photoprotection / sunless-tanning agent. It has never been approved by the FDA or any other regulator for any indication; clinical development was abandoned and it is sold only via grey-market research-chemical channels. Genuine safety signals have been reported, including darkening of existing moles, eruptive atypical nevi, and case reports of new primary melanoma in young tanning-seeking users.
Kisspeptin-10
Melanotan II
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Kisspeptin-10
Melanotan II
COA corpus from Disclosed Labs — independently tested batches only.
Kisspeptin-10
50
COAs
99.6%
Avg purity
11
Labs
Melanotan II
60
COAs
99.7%
Avg purity
12
Labs
The foundational role of kisspeptin in reproduction was established by de Roux et al. (PNAS, 2003, PMID 12944565) and Seminara et al. (NEJM, 2003, PMID 14573733), who identified loss-of-function mutations in GPR54 causing hypogonadotropic hypogonadism. Dhillo et al. (JCEM, 2005) showed kisspeptin-54 stimulates LH, FSH, and testosterone in men; George et al. (JCEM, 2011, PMID 21632807) confirmed IV kisspeptin-10 boluses stimulate LH and increase pulse frequency in men. Young et al. (Neuroendocrinology, 2012, PMID 22377698) showed kisspeptin infusion restores pulsatile LH in patients with neurokinin B (TAC3/TACR3) signaling deficiencies. Abbara/Jayasena and colleagues (JCEM 2015, PMID 26192876; Hum Reprod 2017, PMID 28854728) demonstrated kisspeptin-54 can trigger oocyte maturation in IVF with very low OHSS rates. The kisspeptin receptor agonist MVT-602 has been in Phase 2 development for female HSDD. Grey-market SubQ use (~200 mcg 2x/week for libido or testosterone support) is not supported by controlled trials.
Key references
Melanotan II was developed by Hruby, Hadley, and colleagues at the University of Arizona in the 1980s. The seminal Phase I clinical study is Dorr et al. (Life Sciences, 1996; PMID 8637402), a pilot trial in three healthy male volunteers that documented dose-dependent pigmentation together with nausea, a 'stretching and yawning complex,' and spontaneous penile erections — the MC4R sexual-arousal signal that later motivated the development of bremelanotide (PT-141/Vyleesi). MT-II itself was never advanced to Phase III and has never received regulatory approval in any jurisdiction. As unregulated consumer use expanded through the 2000s, dermatology literature accumulated safety signals: Langan et al. (BMJ 2009, PMID 19174439) reported changes in moles among young users of unlicensed 'sun tan jab' preparations; Cardones & Grichnik (Arch Dermatol 2009, PMID 19380666) described alpha-MSH-induced eruptive atypical nevi in a patient with dysplastic nevi and prior melanoma who used MT-II; Evans-Brown et al. (BMJ 2009, PMID 19224885) documented widespread unregulated population use. Further case reports describe new primary cutaneous melanoma in young MT-II users and rare rhabdomyolysis. Regulators (FDA, UK MHRA, Australian TGA) have explicitly warned against use. Note: the Barnetson et al. 2006 photoprotection study (J Invest Dermatol, PMID 16763547) evaluated the related linear analog [Nle4-D-Phe7]-alpha-MSH (afamelanotide / Melanotan-I), not MT-II. Category 2 classification reflects documented safety concerns from non-selective melanocortin activation combined with oncologic signals.
Kisspeptin-10 (Hormone) and Melanotan II (Cosmetic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs